Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sutent and Stereotactic Radiation for Oligometastatic Disease
NCT00463060Phase 2Completed
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Jan 2007
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sunitinib in oligometastatic disease (OMD), sponsored by Icahn School of Medicine at Mount Sinai. Started Jan 2007; status: completed.
02
Drugs
sunitinib
03
Conditions
oligometastatic disease (OMD)
Beyond the preview
Go deeper on NCT00463060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00463060.